Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)
24 oct. 2024 08h01 HE
|
Intellia Therapeutics, Inc.
Deep attack rate reductions achieved in both dose levels tested; a single 50 mg dose resulted in a mean monthly attack rate reduction of 77% and 81% compared to placebo during weeks 1-16 and 5-16,...
CRISPR-based Gene Editing Market Report 2024-2030, Featuring Revvity, Danaher, GenScript, Merck, Tocris Bioscience, OriGene Technologies, Bio-Rad Laboratories, Bio-Techne & New England Biolabs
21 oct. 2024 10h54 HE
|
Research and Markets
Dublin, Oct. 21, 2024 (GLOBE NEWSWIRE) -- The "CRISPR-based Gene Editing Market Size, Share and Trends Analysis Report by Product & Service (CRISPR Kits & Reagents), Application (Biomedical,...
Intellia Therapeutics Announces Initiation of HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)
07 oct. 2024 07h30 HE
|
Intellia Therapeutics, Inc.
NTLA-2002 is a single-dose treatment designed to prevent potentially life-threatening swelling attacks in people with hereditary angioedema (HAE)NTLA-2002 is Intellia’s second in vivo candidate to...
Intellia Therapeutics to Present New Clinical Data from the Phase 1 Study of nexiguran ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2024 AHA Scientific Sessions
01 oct. 2024 07h30 HE
|
Intellia Therapeutics, Inc.
New data to be presented will include biomarkers of disease progression and functional capacity from the ongoing Phase 1 study of nex-z, an investigational in vivo CRISPR gene editing therapy for ATTR...
Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting
12 sept. 2024 07h30 HE
|
Intellia Therapeutics, Inc.
First presentation of detailed Phase 2 results following previous positive topline announcement that study of NTLA-2002 met primary and all secondary endpoints Intellia to host investor webcast on...
Gene Editing Therapeutics Market Forecast 2024-2029: A $1 Billion Market by 2029, with a Forecasted CAGR of 147%
10 sept. 2024 04h51 HE
|
Research and Markets
Dublin, Sept. 10, 2024 (GLOBE NEWSWIRE) -- The "Gene Editing Therapeutics Market" report has been added to ResearchAndMarkets.com's offering.The gene editing therapeutics market is estimated to be...
Gene Therapy Market Size, Share & Trends Analysis Report 2024-2030, By Indication, By Vector Type, By Route Of Administration, By Region and Segment Forecasts
20 août 2024 06h28 HE
|
Research and Markets
Dublin, Aug. 20, 2024 (GLOBE NEWSWIRE) -- The "Gene Therapy Market Size, Share & Trends Analysis Report By Indication (Acute Lymphoblastic Leukemia, Large B-cell Lymphoma), By Vector Type...
CRISPR Gene Editing Market Size Projected to Surpass $2 Billion by 2024 Amid Increasing Demand for Genetic Treatments - Long-term Forecast to 2028 and 2033
15 août 2024 09h57 HE
|
Research and Markets
Dublin, Aug. 15, 2024 (GLOBE NEWSWIRE) -- The "Global CRISPR Gene Editing Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The CRISPR gene editing market has...
CRISPR and Cas Gene Global Research Report 2024 | Now Available
01 août 2024 06h10 HE
|
Research and Markets
Dublin, Aug. 01, 2024 (GLOBE NEWSWIRE) -- The "CRISPR and Cas Gene Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The crispr and cas gene market size has...
Adeno-associated Virus Gene Therapy Market Report 2024-2034: Epidemiology, Industry Trends and Forecasts
21 juin 2024 06h05 HE
|
Research and Markets
Dublin, June 21, 2024 (GLOBE NEWSWIRE) -- The "Adeno-associated Virus Gene Therapy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034" report has been...